SOUTHWEST ONCOLOGY GROUP

$210,509U10FY2003CANIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Paper 32816893 Paper 28994212 Paper 28579151 Paper 27475087 Paper 26577691 Paper 26200977 Paper 25611229 Paper 25536215 Paper 25422488 Paper 25332243 Paper 25250858 Paper 25219358 Paper 25188482 Paper 25041791 Paper 25002722 Paper 24995683 Paper 24994597 Paper 24888818 Paper 24752945 Paper 24749780 Paper 24712482 Paper 24663049 Paper 24616308 Paper 24528179 Paper 24411921 Paper 24383843 Paper 24352574 Paper 24171516 Paper 24166832 Paper 24144643 Paper 24130072 Paper 24092933 Paper 24057042 Paper 24022189 Paper 24010120 Paper 23999597 Paper 23871417 Paper 23591789 Paper 23550669 Paper 23524864 Paper 23306462 Paper 23233710 Paper 23226204 Paper 22981891 Paper 22853014 Paper 22585691 Paper 22267853 Paper 22228638 Paper 21964533 Paper 21896650 Paper 21873548 Paper 21826527 Paper 21810677 Paper 21782524 Paper 21766209 Paper 21551228 Paper 21502546 Paper 21455999 Paper 21415234 Paper 21334731 Paper 21169260 Paper 21113977 Paper 21105991 Paper 20921467 Paper 20881645 Paper 20876454 Paper 20631636 Paper 20606093 Paper 20484019 Paper 20376086 Paper 20309628 Paper 20211359 Paper 20194851 Paper 20150438 Paper 20124181 Paper 20044128 Paper 20005174 Paper 20004966 Paper 19884559 Paper 19821823 Paper 19770625 Paper 19770418 Paper 19752340 Paper 19723641 Paper 19671875 Paper 19620488 Paper 19557750 Paper 19546405 Paper 19517476 Paper 19470925 Paper 19433682 Paper 19380444 Paper 19371909 Paper 19364954 Paper 19167731 Paper 19130298 Paper 19100570 Paper 19096312 Paper 19001327 Paper 18931340

Abstract

Description (Adapted from the applicant s abstract): This grant allows the University of Michigan to continue to participate in the activities and study protocols of the Southwest Oncology Group which involve development and testing of investigational therapies in patients with solid tumor or hematologic malignancies that have less than 100 percent cure rates with standard therapies. They believe that the pooling of patient data from multiple institutions is a scientifically valid and efficient method for quickly evaluating new therapeutic strategies. They participate in three specific areas of this cooperative group process: (1) significant patient accrual onto group studies, (2) scientific and administrative contributions to the development and coordination of group studies, and (3) act as the administrative scientific and quality control link between several community oncologist (cancer control affiliates) and the Southwest Oncology Group.

View original record on NIH RePORTER →